Atractylenolide I
Based on 6 publication(s) in Google Scholar
Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.98%
- CAS No.: 73069-13-3
- Formule: C15H18O2
- Masse moléculaire:230.30
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-N0203
Atractylenolide IIIApoptosis Inducer -
HY-N0202
Atractylenolide IIApoptosis Inducer -
HY-N0102
IsoliquiritigeninAutophagy Inducer -
HY-N0184
Glycyrrhizic acidHMGB1 Antagonist -
HY-B0094
ArtemisininParasite Inhibitor -
HY-N0703
SchaftosideFlavonoid -
HY-N0822
ShikoninChloride Channel Inhibitor -
HY-N0155
NobiletinROR Agonist -
HY-10626
T0901317LXR Agonist -
HY-17031
SBE-β-CDExcipient -
HY-N0040
Ginsenoside Rb2Influenza Virus Inhibitor -
HY-D1056
Lipopolysaccharides, from E. coli O55:B5Endotoxin
Publications Citing Use of MedChemExpress (MCE) Atractylenolide I
More
Customer Validation & Images
-
IHC
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
Cell Migration/Invasion Assay
-
WB
Voir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
Description
IC50 & Target
|
TLR7 |
TLR9 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Jurkat | IC50 |
24.44 μg/mL
Compound: ATL-1
|
Cytotoxicity against human Jurkat T cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human Jurkat T cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26988300] |
| Jurkat | IC50 |
37.63 μg/mL
Compound: ATL-1
|
Cytotoxicity against human Jurkat T cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human Jurkat T cells assessed as growth inhibition after 24 hrs by MTT assay
|
[PMID: 26988300] |
| Jurkat | IC50 |
44.67 μg/mL
Compound: ATL-1
|
Cytotoxicity against human Jurkat T cells assessed as growth inhibition after 12 hrs by MTT assay
Cytotoxicity against human Jurkat T cells assessed as growth inhibition after 12 hrs by MTT assay
|
[PMID: 26988300] |
| U-937 | IC50 |
14.91 μg/mL
Compound: ATL-1
|
Cytotoxicity against human U937 cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human U937 cells assessed as growth inhibition after 24 hrs by MTT assay
|
[PMID: 26988300] |
| U-937 | IC50 |
24.11 μg/mL
Compound: ATL-1
|
Cytotoxicity against human U937 cells assessed as growth inhibition after 12 hrs by MTT assay
Cytotoxicity against human U937 cells assessed as growth inhibition after 12 hrs by MTT assay
|
[PMID: 26988300] |
| U-937 | IC50 |
4.23 μg/mL
Compound: ATL-1
|
Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26988300] |
In Vitro
Atractylenolide I (40, 60, 80, 100, 120, 150 μM) dose- and time-dependently reduces the cell viability in human A375 melanoma cells after treatment for 24, 48 and 72 hours. Atractylenolide I (50 and 100 μM) induces apoptosis of A375 cells in a dose-dependent manner at 48 h of treatment. Atractylenolide I (100 μM) significantly reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, without effect on total JAK2 and STAT3. Furthermore, Atractylenolide I inhibits the mRNA expression of STAT3-targeted genes, including Bcl-xL, MMP-2 and MMP-9[1]. Atractylenolide I (up to 100 μM) shows no toxicity in normal cells. Atractylenolide I (25, 50 μM) decreases the Ox-LDL induced TNF-α, IL-6 and NO production in VSMCs. Atractylenolide I (12.5, 25 or 50 μM) significantly reduces the level of MCP-1 and inhibits Ox-LDL-induced VSMCs proliferation and migration. Atractylenolide I (25, 50 μM) inhibits positive staining of foam cells, and also significantly decreases lipid accumulation. Atractylenolide I (50 μM) suppresses p38MAPK and NF-κB p65 expression in VSMCs stimulated by Ox-LDL[3]. Atractylenolide I (1, 10, 100 μM) downregulates paclitaxel-induced expression of VEGF and survivin via MyD88-dependent TLR4 signaling in EOC cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 73069-13-3
-
Appearance Solid
-
Masse moléculaire 230.30
-
Formule C15H18O2
-
Color White to light yellow
-
SMILES
O=C1C(C)=C(C[C@@]23[H])C(O1)=C[C@@]3(C)CCCC2=C
-
Structure Classification
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Autophagy
Atractylenolide I inhibits angiogenesis and reverses sunitinib resistance in clear cell renal cell carcinoma through ATP6V0D2-mediated autophagic degradation of EPAS1/HIF2α. [Abstract]2025 Mar;21(3):619-638. PMID: 39477683
Atractylenolide I purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Mar;21(3):619-638. [Abstract]
VEGFA IHC staining in control and ATL-I (80 μM or 160 μM)-treated Matrigel plugs. Quantification of vegfa-positive cells. Scale bar: 100 μm. In the present set of experiments, Bevacizumab (50 ng/ml) was used as the positive control.
-
Nat Commun
A small secreted protein triggers a TLR2/4-dependent inflammatory response during invasive Candida albicans infection. [Abstract]2019 Mar 4;10(1):1015. PMID: 30833559 -
Phytother Res
Atractylenolide I improves behaviors in mice with depression-like phenotype by modulating neurotransmitter balance via 5-HT2A. [Abstract]2024 Jan;38(1):231-240. PMID: 37857401 -
Chin Med
Atractylenolide I ameliorated the growth and enzalutamide resistance of castration-resistant prostate cancer by targeting KIF15. [Abstract]2025 Mar 14;20(1):35. PMID: 40087774
Atractylenolide I purchased from MedChemExpress. Usage Cited in: Chin Med. 2025 Mar 14;20(1):35. [Abstract]
Cell viability analysis of C4-2 and PC-3 after treatment with indicated concentrations of Atractylenolide (AITR-I) (40, 80, 120, 160, 200 μM) for 48 or 72 h.
Atractylenolide I purchased from MedChemExpress. Usage Cited in: Chin Med. 2025 Mar 14;20(1):35. [Abstract]
EdU staining of proliferated cells treated with Atractylenolide I (ATR-I) (80, 120 μM).
Atractylenolide I purchased from MedChemExpress. Usage Cited in: Chin Med. 2025 Mar 14;20(1):35. [Abstract]
The metastatic ability of CRPC cells was assessed by wound healing assay treated with Atractylenolide I (ATR-I) (80, 120 μM, 24, 48 h).
Atractylenolide I purchased from MedChemExpress. Usage Cited in: Chin Med. 2025 Mar 14;20(1):35. [Abstract]
The expression of genes related with epithelial–mesenchymal transition (EMT) was measured by western blotting treated with Atractylenolide I (ATR-I) (80, 120 μM).
Atractylenolide I purchased from MedChemExpress. Usage Cited in: Chin Med. 2025 Mar 14;20(1):35. [Abstract]
The apoptosis rate was tested using flow cytometry treated with Atractylenolide I (ATR-I) (80, 120 μM).
-
-
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (434.22 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.86 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.86 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (283 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Atractylenolide I, et al. The JAK2/STAT3 pathway is involved in the anti-melanoma effects of atractylenolide I. Exp Dermatol. 2018 Feb;27(2):201-204. [Content Brief]
[2]. Gao H, et al. Anti-depressant-like effect of atractylenolide I in a mouse model of depression induced by chronic unpredictable mild stress. Exp Ther Med. 2018 Feb;15(2):1574-1579. [Content Brief]
[3]. Li W, et al. Atractylenolide I restores HO-1 expression and inhibits Ox-LDL-induced VSMCs proliferation, migration and inflammatory responses in vitro. Exp Cell Res. 2017 Apr 1;353(1):26-34. [Content Brief]
[4]. Huang JM, et al. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway. Sci Rep. 2014 Jan 23;4:3840. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.3422 mL | 21.7108 mL | 43.4216 mL | 108.5541 mL |
| 5 mM | 0.8684 mL | 4.3422 mL | 8.6843 mL | 21.7108 mL | |
| 10 mM | 0.4342 mL | 2.1711 mL | 4.3422 mL | 10.8554 mL | |
| 15 mM | 0.2895 mL | 1.4474 mL | 2.8948 mL | 7.2369 mL | |
| 20 mM | 0.2171 mL | 1.0855 mL | 2.1711 mL | 5.4277 mL | |
| 25 mM | 0.1737 mL | 0.8684 mL | 1.7369 mL | 4.3422 mL | |
| 30 mM | 0.1447 mL | 0.7237 mL | 1.4474 mL | 3.6185 mL | |
| 40 mM | 0.1086 mL | 0.5428 mL | 1.0855 mL | 2.7139 mL | |
| 50 mM | 0.0868 mL | 0.4342 mL | 0.8684 mL | 2.1711 mL | |
| 60 mM | 0.0724 mL | 0.3618 mL | 0.7237 mL | 1.8092 mL | |
| 80 mM | 0.0543 mL | 0.2714 mL | 0.5428 mL | 1.3569 mL | |
| 100 mM | 0.0434 mL | 0.2171 mL | 0.4342 mL | 1.0855 mL |
Atractylenolide I Related Classifications
HY-N0201 Related Classifications
Powered by Bioz